The health ministry’s Central Social Insurance Medical Council (Chuikyo) on June 22 approved the expedited NHI price listing of Japan Tobacco’s anti-HIV drug Genvoya (elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide (TAF)). The drug will be listed on June…
To read the full story
Related Article
- Anti-HIV Drug Genvoya Approved in Japan
June 20, 2016
REGULATORY
- Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- Solo Distribution Poses Threats to Stable Supplies, Price Negotiations: Survey
December 17, 2025
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





